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There is a dire need to discover new targets for Alzheimer’s disease (AD) drug development. Decreased neuronal glucose
metabolism that occurs in AD brain could play a central role in disease progression. Little is known about the compensatory
neuronal changes that occur to attempt to maintain energy homeostasis. In this review using the PubMed literature database, we
summarize evidence that amino acid oxidation can temporarily compensate for the decreased glucose metabolism, but eventually
altered amino acid and amino acid catabolite levels likely lead to toxicities contributing to AD progression. Because amino acids
are involved in so many cellular metabolic and signaling pathways, the effects of altered amino acid metabolism in AD brain are
far-reaching. Possible pathological results from changes in the levels of several important amino acids are discussed. Urea cycle
function may be induced in endothelial cells of AD patient brains, possibly to remove excess ammonia produced from increased
amino acid catabolism. Studying AD from a metabolic perspective provides new insights into AD pathogenesis and may lead to
the discovery of dietary metabolite supplements that can partially compensate for alterations of enzymatic function to delay AD or
alleviate some of the suffering caused by the disease.

1. Introduction
There are currently about 24 million cases of Alzheimer’s
disease (AD) worldwide, and that number is expected to
continue to increase for at least the next few decades as better
treatments for other diseases such as heart disease and cancer
extend average human longevity [1]. In addition to human
suffering, Alzheimer’s disease and other dementias cost the
United States about $172 billion in 2010 [2]. To date, a majority
of research has focused on the amyloid cascade hypothesis
that emphasizes the role of amyloid-𝛽 protein aggregation in
the pathogenesis of AD. However, growing evidence suggests
that the amyloid cascade hypothesis does not encapsulate
the complex symptomology of AD [3]. Two decades of
researching the amyloid cascade hypothesis have not yielded
the treatments that were predicted in the early 1990s. The
other major histological hallmark of AD brain in addition
to amyloid plaques is the neurofibrillary tangle pathology
resulting from hyperphosphorylation and aggregation of tau
protein [3]. It is possible that tau-based therapies will not
fare better in clinical trials than amyloid-based therapies.

Another promising alternative is to view Alzheimer’s disease
as a metabolic disease in attempt to shed novel insight into
its etiology. In this regard, it is known that neurons in AD
brain show large deficits in glucose metabolism, so alternative
energy sources may help to prevent the neuronal death characteristic of the disease. Treating AD as a metabolic disorder
would lead to further research into dietary supplementation
of metabolites and enzyme cofactors. One such strategy is to
supplement with factors that are depleted in AD brain, while
another strategy is to supplement with metabolites that can
be oxidized to provide energy for neurons. Neurons lack the
enzymes for beta-oxidation of fatty acids, but other possible
neuronal energy sources include amino acids, ketone bodies,
citric acid cycle intermediates, pyruvate, and lactate. Because
many recent metabolomics investigations have shown large
changes in the levels of several amino acids in AD brain and
plasma, it is important to consider whether changes in amino
acid metabolism are a driving force for AD progression.
Amino acids in the form of proteins are a large part of
the human diet. The recommended daily allowance of protein
is 0.8 grams per kilogram body mass [4]; in an average
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adult this amounts to roughly 71 grams of protein per day.
This high protein consumption dictates that amino acids will
be present at levels that far exceed their requirements as
the building blocks for protein synthesis, and most of the
protein consumed will be broken down for energy generation.
Processing these amino acids for energy generation requires
the disposal of nitrogenous waste, a process carried out
mostly in the liver and small intestine by the urea cycle.
Disrupted amino acid and nitrogen metabolism is associated
with neurological defects and in some cases dementia [5–
9]. In addition to these primary routes of amino acid usage,
amino acids and their metabolic derivatives are involved to a
lesser extent in cell signaling and in many diverse metabolic
pathways.

2. Amino Acid Metabolism in the AD Brain
Many studies have shown altered amino acid levels in serum
and brain in AD patients or in AD model mice, but whether
or not these changes contribute to disease pathogenesis is not
yet known. Because glutamate is an excitatory neurotransmitter and one of its metabolites, gamma-aminobutyric acid
(GABA), is an inhibitory neurotransmitter [9], changes in
glutamate metabolism in AD brain could greatly affect neural
functioning. GABA can also be synthesized from arginine in
astrocytes and increased GABA levels synthesized through
this pathway have been shown to play a role in cognitive
dysfunction in an AD mouse model [31]. Changes in the
levels of enzymes involved in amino acid metabolism have
also been observed in AD brain [32], further suggesting a
role for metabolic dysregulation in AD pathogenesis. For
example, alterations in the levels of glutamine synthetase and
urea cycle enzymes and intermediates have been observed
in AD brain. This is of concern because nitrogenous waste
in the form of ammonia from amino acid catabolism has
adverse effects on neural cells if not properly cleared from the
brain.
A healthy individual is able to process the excess amino
acids consumed into other useful metabolites or oxidize them
for energy production. To use them as fuel, the carbon skeletons are oxidized in the citric acid cycle to produce carbon
dioxide, and the excess nitrogen is disposed of as the relatively
nontoxic nitrogenous waste product urea. However, when
neurons cannot catabolize glucose efficiently, such as during
AD, they may become reliant upon amino acid oxidation for
energy production. If neuronal amino acids become depleted
or if the machinery used to metabolize amino acids becomes
dysregulated, the neurons may die, contributing to disease
progression. However, even if amino acid oxidation is able
to maintain neuronal energy levels, the increased amounts
of ammonia released during amino acid catabolism could
lead to neuronal cell death because all of the enzymes of
the urea cycle needed to detoxify ammonia are not present
in neurons or glia. Instead, astrocytes express high levels
of the glutamine synthetase enzyme to sequester ammonia
into glutamine, which is then released from the brain. Due
to the 40-fold lower expression of glutamine synthetase in
neurons, they are not equipped to detoxify the excess ammonia.
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3. Amino Acid Level Changes in Control,
MCI, and AD Populations
Identifying amino acid changes in patients with mild cognitive impairment (MCI) is important as these changes may
be upstream changes leading to the onset of AD, and the
downstream changes that occur during AD may be a result
of the body adapting to the insults that occurred during
MCI. In one report, a metabolomics analysis was performed
on the cerebrospinal fluid (CSF) of patients with MCI, AD,
or healthy aged-matched controls. Results showed that the
metabolites dimethylarginine, arginine, valine, proline, serine, histidine, choline, creatine, carnitine, and suberylglycine
were possible disease progression biomarkers [33]. Another
group studying potential CSF biomarkers for AD concluded
that changes in methionine, tryptophan, tyrosine, and purine
metabolism pathways occurred in both MCI and AD subjects. Methionine levels increased in MCI while tryptophan
levels decreased [34]. Levels of the tripeptide glutathione also
decreased in AD. One study found increased cysteine levels
in CSF from AD subjects [28], while another one identified
altered tryptophan and phenylalanine levels in plasma from
both MCI and AD subjects compared to controls; tryptophan
levels were also distinct when comparing MCI to AD subjects
[35]. A further metabolomics study of plasma found altered
arginine metabolism and polyamine metabolism in MCI and
AD subjects [36]. Another study found that glycine and valine
levels were altered in AD plasma [37], but the authors warned
that plasma amino acid levels show large variability depending upon the amount of fasting the subjects had undergone
prior to donating blood [38] and that phospholipids may be
more reliable plasma biomarkers.
A comprehensive metabolomics study of both plasma
and CSF from control, MCI, and AD subjects found that
tryptophan and arginine metabolism were altered in both
CSF and plasma from MCI subjects [39]. Lysine metabolism
was decreased in the CSF but not plasma from the MCI
subjects. This study also found increased methionine levels
in the CSF of MCI subjects. Methionine, histidine, and lysine
levels were increased in AD plasma. The pathways affected
in both AD CSF and plasma included beta-alanine, aspartate
and asparagine, alanine, cysteine, methionine, methioninecysteine-glutamate, and arginine and lysine metabolism.
Phenylalanine, lysine, and leucine were three of six metabolites in plasma that could be used to discriminate between
the MCI subjects and controls [39]. A salivary metabolomics
analysis found that taurine and several dipeptides including
Ser-Ser, Phe-Pro, and Arg-Leu were decreased in abundance
in MCI patients [40]. From the summation of these results
one can discern that there are many alterations in amino acid
metabolism in MCI and AD patients, but the results are not
very consistent from study to study likely due to the different
methodologies and instrumentation used.

4. An Overview of Select Amino Acids by Class
In MCI and AD subjects, some amino acids increased in
abundance while most decreased in abundance, especially
in the brain, consistent with their oxidation as a neuronal
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Table 1: Free amino acid abundance changes in Alzheimer’s disease.
Amino acid

Tissue or fluid
measured

Increase or
decrease in AD

Points of interest
Strong mTOR activator
[10]; 𝛼-ketoacid metabolite
led to metabolic
dysfunction [10–12]

Leucine

Phenylalanine

Serum [14];
brain [15, 16]

Decrease [14];
increase [15, 16]

mTOR activator [10];
𝛼-ketoacid metabolite led
to oxidative stress [10]
mTOR activator [10];
𝛼-ketoacid metabolite led
to oxidative stress [10]
Metabolized in the absence
of tyrosine [17]

Tryptophan

Serum [14];
brain [15]

Decrease [14];
increase [15]

Metabolite causes
metabolic dysfunction [18]

Tyrosine

Serum [14]

Decrease [14]

Decrease levels could
disrupt catecholamine
production

Serum [21];
brain [22]
Brain [15, 22];
serum [14]
Serum [23];
brain [15, 22]
Brain [15]
Serum [14]
Serum [26, 27];
brain [15, 26];
CSF [28]

Decrease [21];
increase [22]
Decrease
[14, 15, 22]
Increase [15];
decrease [22, 23]
Decrease [15]
Decrease [14]
Decrease [26];
increase
[15, 27, 28]

Serum [27]

Decrease [27]

Valine

Plasma [14]

Decrease [14]

Isoleucine

Glutamine
Aspartic acid
Glutamic acid
Lysine
Histidine
Cysteine
Methionine

Effects of addition
Metabolite led to
mitochondrial dysfunction
in rat neurons [12]; BCAAs
increased mean lifespan of
male mice [13]
BCAA-fortified diet
increased mean lifespan of
male mice [13]
BCAA-fortified diet
increased mean lifespan of
male mice [13]

DataWarrior
Drug Score∗

0.592

0.559

0.684
0.579

Metabolite increases nitric
oxide synthetase in cell
culture [19]
Improved memory and
cognitive function in
humans [20]

0.661

0.584
0.573
0.593

Excitotoxicity leads to
neuronal death [24, 25]

0.531
0.499
0.835

Involved in glutathione
synthesis; mTOR inhibitor

Decreased mTOR activity
in rats [29]

0.493

mTOR activator

Increased amyloid-beta and
p-tau in mice [30]

0.578

∗
Structures were drawn using DataWarrior software using their most prevalent charge states at pH 7.4. A higher drug score value indicates a better drug
candidate.

energy source. This information is summarized in Table 1.
There are several possible mechanisms described in detail
below through which altered metabolism of specific amino
acids may lead to neural pathogenicity.
4.1. Branched Chain Amino Acids, mTOR, and AD. The
branched chain amino acids (BCAAs) include leucine, valine,
and isoleucine. BCAAs compete with the aromatic amino
acids phenylalanine, tyrosine, and tryptophan for entry into
the brain. Therefore, altering plasma BCAA levels can affect
the levels of the neurotransmitters serotonin, dopamine,
epinephrine, and norepinephrine in the brain [41]. Unlike
most amino acids which are metabolized to a large extent
by first pass hepatic metabolism, BCAAs are not metabolized
there to a large degree, so their concentration in blood often
directly reflects the level of dietary consumption. Protein
restriction has been shown to decrease tau hyperphosphorylation and increase cognition in an AD mouse model [42].
A BCAA-restricted diet has been shown to induce protective
metabolic effects on peripheral glucose and insulin levels in

a similar manner as a protein restricted diet [43]. However,
whether the neuroprotective effects of protein restriction are
mediated by decreased BCAA levels is not yet known as
restriction of other amino acids such as methionine can also
lead to protective metabolic effects [44].
Some researchers suspect a link between increased BCAA
levels and AD pathogenesis [45]. Increasing BCAA levels
through dietary supplementation in rats led to a decrease in
neural growth factor (NGF) in the hippocampus [46], a part
of the brain involved in memory formation and known to
undergo extensive neuronal loss in AD patients. Administration of the leucine metabolite 𝛼-ketoisocaproic acid also
decreased NGF as well as brain-derived neurotrophic factor
(BDNF) [11]. However, the role of BCAAs in AD is not clearcut. The level of one of the BCAAs, valine, was found to be
decreased in the plasma of AD patients [14]. Furthermore,
there are several studies that link increased levels of BCAAs
to indicators of increased health such as increased muscle
protein synthesis [47], mitochondrial biogenesis [13], and
mTOR signaling [48]. A beneficial role of mTOR signaling
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in AD has been hypothesized due to the fact that insulin
signaling is neuroprotective [49, 50], and insulin can activate
mTOR kinase through PI3K [51, 52]. mTOR activity has also
been found to be neuroprotective under other experimental
conditions. For example, increased mTOR activation was
associated with decreased A𝛽 pathology in brains from the
5xFAD mouse model [53]. However, these effects may be
related to the particular model or to the length of time
of mTOR activation. In the short term, it appears that
mTOR activation can lead to improved insulin secretion [54],
whereas chronic mTORC1 activation may lead to exhaustion
of 𝛽-cells in the pancreas [55], decreasing the levels of
neuroprotective insulin.
Somewhat contrary to the findings of mTOR being
neuroprotective is the finding that increased mTOR activation is frequently found in the brains of AD model mice
[56] and human AD patients [57]. Increased amyloid-beta
levels lead to increased mTOR activation, which increases
protein translation to increase levels of tau protein, the
main component of the neurofibrillary tangles pathologically
found in AD neurons [58]. The increased rate of translation
induced by mTOR activation may be partially responsible for
the decreased levels of amino acids measured in AD brain.
Increased mTOR activity can also stimulate mitochondrial
electron transport chain activity [59], perhaps leading to
increased mitochondrial catabolism of amino acids. The
increased mTOR activity also decreases the rate of autophagy,
leading to the buildup of toxic amyloid-beta peptides. Consistent with these findings, treatment of PDAPP or 3xTg-AD
mice with rapamycin, an mTOR inhibitor, reduced amyloidbeta and tau levels and restored cognitive function [60, 61].
These data suggest that diets containing low protein levels
or low levels of the potent mTOR activators leucine and
arginine may prove beneficial for AD patients [62], although
decreasing the levels of all three BCAAs together was more
potent than decreasing only leucine levels on enhancing
peripheral metabolism in mice [43].
Since a portion of the protective effects of mTOR inhibition by rapamycin treatment in AD model systems results
from a decreased rate of translation, other therapies which
decrease the rate of translation in the brain may also be
therapeutic. With this in mind, decreased or unbalanced
amino acid levels have also been shown to decrease the rate
of translation through the general control nonderepressible
2- (GCN2-) eIF2𝛼 kinase pathway. GCN2 kinase senses
uncharged tRNAs and then phosphorylates the translation
initiation factor eIF2𝛼 to slow the rate of translation. As
mentioned above, many amino acids, for example, BCAAs
and aromatic amino acids, share the same amino acid transporter for transport across the blood-brain barrier. Therefore,
supplementation with high levels of one particular amino
acid may decrease the rate of transport of others into the
brain to decrease their levels. This could create imbalanced
amino acid levels in the brain to activate GCN2 and inhibit
mTOR, decreasing global translation rates and increasing
autophagy to protect AD brains. Not all mRNA transcripts
show decreased translation under amino acid limitation.
Some transcripts such as ATF4 show increased translation
to mediate protective compensatory responses. ATF4 is a
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transcription factor involved in the ER stress response that
has been shown to be upregulated in liver during five
conditions that extended mouse longevity [63].
There are two prevalent hypotheses linking BCAAs to
metabolic disease [10]. First, increased levels of BCAAs,
especially leucine, may directly lead to persistent activation
of mTORC1. Second, hyperactivation of BCAA catabolism
can lead to increased BCAA metabolites which lead to
metabolic dysfunction. For example, adding the 𝛼-ketoacid
catabolite of leucine, 𝛼-ketoisocaproic acid, to rat neurons
led to mitochondrial dysfunction [12]. The conflicting results
of studies attempting to find correlations between BCAA
levels and disease suggest a complex role for BCAA levels in
metabolism that may vary depending on the model organism,
disease state, and the length of time of elevated BCAA and
BCAA catabolite levels.
Few studies have examined the levels of BCAAs specifically in postmortem AD brain, but it appears that increasing
certain BCAAs may be beneficial for the aging brain in
specific model systems. A diet high in BCAAs has even
been shown to increase the mean lifespan of male mice [13].
Research into the role of BCAAs in AD is far from complete.
For example, there has been little study of the effects of
isoleucine or valine supplementation in AD patients or
animal models. Since isoleucine and valine do not stimulate
mTOR activity as potently as leucine [64] and are not broken
down into neurotoxic 𝛼-ketoisocaproic acid, supplementation with these amino acids could provide energy for the
brain without activating potentially pathogenic signaling
pathways. Given the links between BCAAs, mTOR signaling,
aging, and neurodegeneration, further research will likely
clarify these complex interactions. Furthermore, many of the
same correlations observed for BCAAs in insulin resistant
individuals have also been observed for aromatic amino
acids, highlighting a complementary role for both of these
classes of amino acids in metabolism and disease [65].
4.2. Aromatic Amino Acids. Several studies have found that
the levels of aromatic amino acids are altered in AD serum
or brain. One research group found a decrease in all three
aromatic amino acids in the serum of AD patients [14],
while others reported an increase in both phenylalanine and
tryptophan in the brains of AD patients [15]. Researchers
using AD model rats found an increase in phenylalanine in
different regions of the brain [16]. In the brain, tryptophan
has two different metabolic fates: it can be metabolized
into serotonin or it can enter the kynurenine pathway
(KP) where it is degraded to 𝛼-amino-𝛽-carboxymuconate-𝜀semialdehyde (ACMS), which can be metabolized either into
quinolinic acid for NAD synthesis or into 2-aminomuconate
for entry into the TCA cycle. Serotonin plays a role in
learning and cognition [66], but enzymes involved in the
KP are upregulated in AD [18]. There is evidence that
quinolinic acid (QUIN) and other metabolic intermediates
in the KP pathway cause oxidative damage to the brain [18].
Increased QUIN led to a concentration-dependent increase
in ROS levels in the synaptosomes of rat brains and lipid
peroxidation in the hippocampus [67]. It has also been shown
that QUIN can increase nitric oxide synthase activity more
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than threefold [19]. This enzyme produces nitric oxide, a
vasorelaxing free radical. Amyloid-beta production increased
the concentration of QUIN [68], linking AD more directly
to oxidative damage from amino acid metabolites. Moreover,
a shift in tryptophan degradation to the KP pathway diverts
tryptophan from the serotonin synthesis pathway. This could
deprive the AD brain of serotonin, contributing to the
pathogenesis of AD. However, knowledge of aromatic amino
acid metabolism and signaling in AD brain is far from
complete. Dietary tryptophan restriction has been shown to
extend the lifespan of rodents [69], but the mechanism has
not been investigated. Acute tryptophan depletion leads to
memory impairment in humans [70].
The amino acid tyrosine is important for synthesizing
catecholamines, but there are only a few studies measuring
tyrosine levels specifically in AD brain, although several
studies have found that oral tyrosine administration improves
memory and cognitive function [20]. Phenylalanine can be
metabolized through the same metabolic pathways as tyrosine, but only when tyrosine levels are low [17], preventing
firm conclusions regarding changes in phenylalanine levels
in AD brain until changes in tyrosine levels are measured as
well. As a class, aromatic amino acid metabolism is especially
important for neural functioning, and more research is
needed to elucidate the relevance of the changes that occur
in AD.
4.3. Charged Amino Acids. The charged amino acids include
the acidic (aspartate and glutamate) and basic (arginine,
lysine, and histidine) amino acids. Each of these appears
to be decreased in AD patient brain or plasma, with the
possible exception of glutamate where the direction of change
may depend upon the brain region assayed. Glutamate [23],
histidine, and aspartate levels were decreased in serum from
AD patients [14], while aspartate and glutamate levels were
decreased in the temporal lobe of the cerebral cortex of AD
patients [22]. Xu et al. measured a decrease in both lysine
and aspartate levels in the brains from autopsied AD patients,
while glutamate levels increased [15]. Glutamate’s interaction
with the NMDA receptor is critical for learning and memory
formation [9], but glutamate excitotoxicity leads to neuronal
death in AD [24, 25]. As discussed below, aspartate and
glutamate also play a role in transamination reactions such
as those occurring upstream of the urea cycle. As a group, the
levels of charged amino acids are altered in AD, suggesting
specific perturbations in metabolism, but more research
needs to be done to determine the causes of the changes
in amino acid levels, the relationship of these changes to
decreased glucose metabolism, and the effects these changes
have on the brain. Examining the activity of more enzymes
involved in amino acid metabolism and building models of
amino acid metabolism could help explain the alterations in
amino acid levels in AD brain.
4.4. Glutamine. Glutamine is the most prevalent amino acid
in plasma, and glutamine and glutamate are the most prevalent amino acids in human brain [71]. Glutamine supplementation decreases tau phosphorylation and has shown
other protective effects such as decreasing inflammation in

5
a mouse model of AD [72]. Glutamine levels decline in AD
patient brain causing a compensatory increased expression
of glutamine synthetase in some neuronal populations. It
has been found that glutamine, glutamate, aspartate, alanine,
and purines are likely degraded as the top alternative energy
sources in neurodegenerative diseases such as AD when
glucose metabolism is disturbed [73]. These amino acids are
readily broken down because high levels of aminotransferases
for the initial step in the catabolism of alanine, aspartate,
and glutamate are present in brain [71]. In one study of
AD patients, glutamine levels were found to decline in the
serum [21] but increase in the temporal cortex of the brain
[22]. Glutamine and alanine levels have also been found to
be decreased in the blood of patients with transient global
amnesia [74].
There has not been much data generated on how the brain
maintains balances of amino acids and total nitrogen levels
during times of neuronal amino acid catabolism, but it is
likely that BCAAs can be taken up through the blood-brain
barrier (BBB) and glutamate can be released to maintain
nitrogen balance [75]. BCAA-derived carbons can then be
fed into the citric acid cycle to form alpha-ketoglutarate,
and then the alpha-ketoglutarate can be transaminated to
glutamate to maintain glutamate levels. During times when
ammonia levels slowly increase in the brain, exporting a
glutamine (containing two nitrogen atoms) from the brain
for every BCAA (or another amino acid containing a single
nitrogen atom) taken up would allow for a net efflux of
nitrogen to lower the brain ammonia levels [71]. However,
this mechanism of removal of nitrogen is likely not robust
enough to deal with large increases in brain ammonia that
are known to cause encephalopathy.
4.5. Sulfur-Containing Amino Acids. The sulfur-containing
amino acids are cysteine and methionine. Much research has
been performed on supplementation with cysteine and the
more membrane permeable form N-acetylcysteine (NAC)
as cysteine levels limit the synthesis of glutathione, one of
the most important antioxidants in the body. Cysteine and
NAC cross the blood-brain barrier slowly, so other therapies are under development to increase brain glutathione
levels [76]. There have been 3 small clinical trials of NAC
supplementation to AD patients with mixed results [77].
Therefore, more research is needed to clarify the effects of
NAC on AD. There seems to be a disruption in sulfurcontaining amino acid metabolism in AD patients as serum
and brain homocysteine levels increase [26]. Cysteine levels
were also shown to be increased in the hippocampus of
autopsied AD patients [15]. Homocysteine-cysteine disulfide
levels were found to increase in AD patient serum while
methionine levels decreased [27]. Increased homocysteine
levels in the plasma are a known risk factor for AD and
other dementias [78]. Dietary methionine supplementation
caused increased amyloid-beta and phosphorylated tau levels
in brain and cognitive impairment in wild-type mice [30].
Dietary methionine restriction led to decreased amyloid-beta
levels and neuroprotection in APP-PS1 AD mice [79] and
decreased mitochondrial complex I-mediated superoxide
production and increased lifespan in rats [80], while cysteine
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supplementation led to a slight decrease in mTOR activity [29]. However, cysteine supplementation prevented the
decreased ROS production in methionine-restricted animals.

5. Amino Acids as an Energy Source in
AD Neurons
One of the hallmarks of AD is dysfunctional energy metabolism. Mitochondrial-derived oxygen free radicals produced
in AD brain are known to damage glycolytic enzymes such
as enolase [81] and glyceraldehyde-3-phosphate dehydrogenase [82], slowing glycolysis. This damage, combined with
decreased insulin signaling in AD brain [83], results in decreased glucose uptake and metabolism which has been
confirmed as an early event in AD progression through the
use of fluorodeoxyglucose (FDG)-PET scans [84]. The decreased glucose metabolism results in decreased pyruvate
production which, combined with amyloid-beta-mediated
mitochondrial complex IV inhibition [85] and tau-mediated
mitochondrial complex I inhibition [86], results in decreased
mitochondrial energy metabolism and ATP levels. Most cells
in the body show metabolic flexibility and can increase mitochondrial fatty acid beta-oxidation to maintain cellular ATP
levels when glycolytic output decreases. Neurons contain
very low levels of fatty acid beta-oxidation enzymes [87], so
they instead rely upon ketone body catabolism, amino acid
catabolism, or catabolism of lactate released from astrocytes
[88] to maintain cellular ATP levels. Ketone body levels are
normally very low in the well-fed and unexercised human
body [89]. Therefore, amino acid catabolism, together with
lactate metabolism and limited glucose metabolism, likely
plays an essential role in maintaining cellular ATP levels in
AD neurons. Data supporting this hypothesis come from
clinical studies that show a 44% decrease in glucose utilization in autopsied early-onset familial AD brain. Surprisingly,
the AD brains showed no deficits in oxygen utilization as free
amino acids (and perhaps lactate) were oxidized for energy
generation in replacement of glucose, leading to decreased
amino acid levels [90]. Once brain amino acid levels were
depleted, brain ammonia levels decreased as well. These data
indicate that amino acid supplementation or high protein
diets may help to energize the AD brain.
The most abundant amino acids present in the human
brain as potential energy sources are glutamate and glutamine, present at roughly 7-8 mM, while the next most abundant amino acids are aspartate and taurine which are present
at roughly 1.2 mM and then serine, GABA, and glycine which
are present at roughly 0.5 mM [71]. The brain contains a
glutamate-glutamine cycle where glutamate is released by
neurons into synaptic clefts; the glutamate is then taken up by
astrocytes where some is broken down for energy, but most is
converted to glutamine which is exported from the astrocytes
and taken up once again by neurons and converted back
into glutamate. To facilitate this cycle, neurons possess high
levels of two glutaminase genes, GLS1 and GLS2 (phosphateactivated mitochondrial glutaminase), to function in the
breakdown of glutamine to glutamate, a process that releases
ammonia, but small amounts of glutaminase (mostly GLS1)
have also been localized to astrocytes [91]. GLS2 activity is
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strongly upregulated by ADP [92] and has been shown to
decline with aging [93], particularly in AD brain [94].
Further release of ammonia in the brain can occur if
glutamate is catabolized to alpha-ketoglutarate by glutamate
dehydrogenase. In addition to the normal mammalian glutamate dehydrogenase gene, GLUD1, primates have a second
glutamate dehydrogenase gene, GLUD2, that is expressed
in astrocytes and may be needed in those cells to preserve
alpha-ketoglutarate levels in the presence of high glutamine
synthetase activity [95]. Glutamine synthetase activity has
been shown to decline in AD brain likely through oxidative
inactivation [96], although protein levels have been shown
to increase in the prefrontal cortex and CSF. Mitochondrial
GLUD1 is negatively regulated by the GTP formed from citric
acid cycle function, while GLUD2 is relatively unaffected by
guanine nucleotides but is positively regulated by ADP and
branched chain amino acids [97]. The negative regulation of
GLUD1 when energy levels are high allows for preservation
of glutamate levels needed for neurotransmission as well as
preventing the toxic buildup of ammonia. Glutamate can also
be metabolized to alpha-ketoglutarate to fuel citric acid cycle
metabolism without the release of free ammonia through
the function of the alanine, aspartate, and branched chain
aminotransferases [98] if the corresponding ketoacids are
present in adequate amounts.
Normally both neurons and astrocytes oxidize glucose by
glycolysis and the resulting pyruvate by oxidative phosphorylation to maximize ATP yield [99]. However, there is much
evidence that indicates astrocytes are more metabolically
flexible than neurons due to their slightly lower energy
demands [100]. Therefore, astrocytes can survive predominately by glycolysis with little oxidative metabolism. In
metabolically stressful times, such as in AD, astrocytes may
convert the pyruvate produced from glycolysis into lactate
to maintain the cellular redox state and then export the
lactate from the cell. The lactate is then taken up by neurons,
converted back into pyruvate, and used for oxidative energy
metabolism, a process called the astrocyte-neuron lactate
shuttle [101]. Astrocytes may also be able to increase the
amount of glutamine released to neurons to be utilized as
an energy source under the pathological conditions when
neuronal glycolysis is impaired. Astrocytes possess some
capability for fatty acid beta-oxidation [87], which likely
becomes more important during these pathological conditions.
A study using AD mice found that a high protein/low
carbohydrate diet resulted in a 5% reduction in the brain
weight in AD mice, including decreased neuronal density and
volume in the CA3 region of the hippocampus that is important for memory [102]. A high protein/low carbohydrate diet
has also been associated with increased excitotoxicity in the
aged brain [103]. These data suggest that high levels of amino
acids or products of their catabolism may contribute to neurodegeneration. Consistent with this assessment, catabolism
of branched chain ketoacids by branched chain ketoacid
dehydrogenase (BCKDH) in mitochondria results in substantial production of damaging superoxide radical [104].
In addition, mice on a low protein/high carbohydrate diet
lived longer than those on a high protein/low carbohydrate
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Figure 1: Overview of the urea cycle. The ammonia that is produced by amino acid catabolism is converted into urea in the urea cycle for
excretion. The metabolic intermediates in the figure are placed in boxes and the enzymes and other necessary substrates are present next to
the arrows. The levels of several of these metabolic intermediates are altered in the brain and plasma of Alzheimer’s disease patients.

diet and had lower insulin levels and lower mTOR activation
[105]. However, the health benefits of a low protein/high
carbohydrate diet may only extend through middle age, as
aged mice or elderly human subjects on a high protein diet
showed protection from disease [106]. Therefore amino acid
supplementation therapies may best be explored as therapies
for late-onset AD. Plasma levels of all three branched chain
amino acids showed a positive correlation with dietary
protein intake in mice, while the plasma levels of most
other amino acids showed a negative correlation with dietary
protein intake. Therefore, some of the beneficial health effects
conferred by the low protein diet in young and middle aged
mice may be mediated by decreased plasma branched chain
amino acid levels.

6. The Urea Cycle and AD
6.1. Amino Acid Metabolism, Ammonia, and the Urea Cycle.
Proteins are digested in the stomach and intestine by several
different peptidases into free amino acids and dipeptides; the
dipeptides are further catabolized into amino acids by first
pass hepatic metabolism. These amino acids are then either
catabolized and used as substrates for gluconeogenesis in the
liver or transported by the blood to other tissues where the
amino acids are used for protein synthesis or broken down
in processes that produce ammonia when levels exceed their
requirements. For this to occur the 𝛼-amino group of the
amino acid is often transferred to 𝛼-ketoglutarate to form
glutamate and an 𝛼-ketoacid, which is oxidized for energy
generation. Glutamate can undergo oxidative deamination
to form ammonia and 𝛼-ketoglutarate, or the amino group
can be transferred to oxaloacetate to form aspartate and

𝛼-ketoglutarate. Aspartate is required for urea cycle function
in the liver. In the brain and muscle (tissues normally lacking
appreciable urea cycle function) aspartate can enter the
purine nucleotide cycle to release fumarate and ammonia.
Other reactions produce ammonia as well; histidine, serine,
threonine, and catecholamine (tyrosine-derived) catabolism
release ammonia through separate reactions. Ammonia is
toxic and needs to be eliminated quickly or converted to
a less toxic form. In peripheral tissues once ammonia and
glutamate combine to form glutamine through the action of
the glutamine synthetase enzyme, the glutamine is exported
from the tissue and transported through the blood to the liver
where the free ammonia is released through the action of the
glutaminase enzyme. The urea cycle then functions to convert
the ammonia to urea, which is excreted from the body.
The first and second steps of the urea cycle occur in
the mitochondria, while the other three steps occur in
the cytoplasm. First, ammonia combines with ATP and
HCO3 − to form carbamoyl phosphate. N-Acetylglutamate is
required as a cofactor for this reaction to proceed. Carbamoyl
phosphate reacts with ornithine to produce citrulline, which
is transported out of mitochondria and then reacts with
aspartate to form argininosuccinate. Argininosuccinate is
converted by argininosuccinase into fumarate and arginine.
In the final step, arginase converts arginine into ornithine and
urea. Figure 1 summarizes amino acid catabolism leading up
to and including the urea cycle.
6.2. Changes in Components of the Urea Cycle in AD. Levels
of enzymes and metabolic intermediates of the urea cycle are
altered in patients with AD. All enzymes required for the urea
cycle are expressed in liver, with low level urea cycle activity
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also occurring in the kidneys and intestines [107]. It has been
shown that normal human brain has very low or no ornithine
transcarbamoylase (OTC) activity, thus preventing urea cycle
activity [108]. Carbamoyl phosphate synthetase activity is also
low in brain tissue. However, studies using autopsied brains
from AD patients have challenged this exclusive localization
of the urea cycle. Hansmannel and colleagues identified
mRNA expression for all enzymes of the urea cycle in the
brains of both normal adults and patients with AD [109].
However, the mRNA levels of OTC were extremely low
in the non-AD subjects, and the normal cytoplasmic urea
cycle enzyme arginase 1 (ARG1) was extremely low in both
populations. Arginase is one of the better studied urea cycle
enzymes with expression that appears to be dysregulated in
AD. Arginase converts arginine to urea and ornithine (see
Figure 1). Two groups, Lui et al. [5] and Hansmannel et
al. [109], found the same trend of increased mitochondrial
arginase II (ARG2) levels in autopsied AD patient brain.
Hansmannel et al. used RT-PCR to find a 55% increase in
ARG2 mRNA levels in AD patients compared to controls
[109], whereas Lui et al. used Western blot to show an increase
in the total amount of ARG2 protein in two different brain
regions with no change in a third [5].
There are several important consequences of increased
ARG2 expression in AD brain. First, increased arginase
activity would likely increase urea and ornithine levels, the
latter being a precursor of polyamine synthesis. Polyamines
can play an important neuroprotective role in the brain.
Second, increased arginase activity would likely decrease
arginine levels, which can lead to decreased mTOR activity. Arginine is also a substrate for nitric oxide synthase
which produces the vasorelaxing free radical nitric oxide
that can increase neuroinflammation. Therefore, transgenic
overexpression of ARG1 showed neuroprotection in a tauoverexpressing model of AD [110]. However, an arginase
inhibitor showed neuroprotective effects in an amyloid-betaproducing mouse model of AD [111]. Therefore, it is possible
that arginase expression has different effects on amyloid and
tau pathology. ARG2 is the main isoform in AD brain and
is highly expressed in endothelial cells. Therefore, it is also
possible that ARG1 activity is neuroprotective while ARG2
activity is neurotoxic due to expression in different cell types
or different subcellular localizations.
Bensemain et al. used RT-PCR to detect the transcription
of the ornithine transcarbamylase (OTC) gene and other
enzymes of the urea cycle in AD brains as well [108]. OTC
activity was exclusively localized to brain endothelial cells,
and its activity in cerebrospinal fluid was nearly 9 times
higher in AD patients than in the control group [108]. It
is interesting that OTC activity was concentrated in the
endothelia in the vasculature of the brain in AD [108]; these
areas are severely affected by amyloid plaques [112]. Taken
together, these results indicate that the urea cycle may occur
in the endothelial cells of AD patients, but this may rely upon
the transport of arginine from the cytoplasm to the mitochondria to be metabolized by ARG2. The mitochondrial
ornithine carriers ORC1, ORC2, and SLC25A29 are also able
to transport arginine [113]. ORC1 and ORC2 are expressed at
very low levels in brain [114], but this may be enough to allow
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low level urea cycle activity in the endothelial cells from AD
patients.
Perhaps the most notable urea cycle metabolite change
in the AD brain is in the level of urea itself. The direction
of the change in level of urea depends on the clinical or
pathological sample or the mouse model tested. Serum from
human AD patients showed a 44% decrease in urea levels
when assayed using GC/MS [14]. The same group found
decreased urea in the serum of APP/PS1 AD model mice [21].
A decrease in urea in the hippocampus of the senescenceaccelerated SAMP8 mice was also measured [115]. SAMP8
mice show neurodegeneration similar to that observed in
AD. The decreased urea levels are consistent with decreased
arginase levels found in APP/PS1 mouse brain [30]. Studies
of human brain show markedly different results. A study
by Gueli and Taibi using GC/MS on temporal lobe extracts
demonstrated that urea was increased in brain tissue of AD
patients over 2-fold [22]. Xu and colleagues measured urea
in six different regions of the brain to find that urea was
increased in AD patients’ brains by an average of more than
5-fold [15]. This increase in urea levels is consistent with the
increased ARG2 levels in human AD brain. Interestingly, in
the striatum of postmortem Huntington’s disease brain, urea
was found to be the most downregulated (3.2-fold) metabolite
[116], but another study found opposite results that urea was
upregulated in all brain regions examined in postmortem
Huntington’s patients [117].
Ornithine levels were decreased in AD brain and serum
[5, 14, 15]. Although ornithine is the product of an enzyme
that is upregulated (ARG2), the decrease is consistent with
other findings because ornithine is the substrate of OTC,
another upregulated enzyme in AD brain [108], and ornithine
is a precursor for the production of polyamines. Consistent
with this reasoning, the level of the polyamine spermidine
was found to increase by 70% in the temporal cortex of AD
brain. [118]. Citrulline levels, however, remain unchanged
in AD brains [5, 119]. Citrulline is a strong antioxidant and
citrulline supplementation prevented age-related changes in
lipid metabolism in mouse hippocampus [120]. Aspartate
reacts with citrulline to form argininosuccinate. Aspartate
levels are decreased in AD patient serum [14], and both
aspartate and arginine levels are decreased in the brain of AD
patients [15, 22]. Decreased levels of urea cycle intermediates
could indicate their efficient metabolism. Considering that
different groups have shown increased urea levels in autopsied AD brains as well as increased expression of one or
more urea cycle genes, current evidence suggests that urea
cycle activity may be induced in endothelial cells from AD
patient brain. It is possible that a urea cycle metabolite such as
arginine that is produced in neurons and glia is imported into
AD endothelial cells where ARG2 levels are high and OTC is
exclusively present to finish the urea cycle there. The citrulline
produced from endothelial cell OTC activity could also be
exported to neurons or glia to finish the urea cycle. However,
it is also possible that the higher urea levels found in AD
brain are strictly due to increased ARG2 levels independent
of complete urea cycle function.
Increased urea levels in AD brain raise questions as
to what could be leading to the increased expression of
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ARG2 (and OTC). The main function of the urea cycle is
to process nitrogenous waste produced from amino acid
catabolism and other sources into a less toxic form before
removal from the body. Therefore, it has been hypothesized
that abnormal nitrogen metabolism may play a role in the
pathogenesis of AD [121]. One of the early hypotheses for
the pathogenesis of AD, proposed by Seiler in 1993, was
the ammonia hypothesis; this posits that increased levels
of ammonia accumulate in and are toxic to the AD brain
[122]. However, the amyloid cascade hypothesis was proposed
the year before [123], and the ammonia hypothesis was
not thoroughly investigated [121]. The ammonia hypothesis
of AD was generated due to the following observations:
increased ammonia levels measured in the plasma from AD
patients [124, 125], decreased glutamine synthetase enzyme
activity in AD astrocytes to scavenge ammonia [96, 126],
increased adenosine deaminase activity in AD brain [127],
and increased monoamine oxidase activity in AD brain [128,
129] (the latter two enzymes produce ammonia). Ammonia
has also been implicated as a cause of oxidative damage in the
brain because it was found to increase reactive oxygen species
levels in SH-SY5Y cells [130] and astrocytes [131] and lead to
RNA oxidation in rats [132].
Furthermore, mitochondrial activity in rat and mouse
models is impaired by ammonia. Ammonia toxicity in
rodent brains led to decreased state III respiration [133] and
decreased cytochrome c oxidase (complex IV) activity [134],
as well as decreased activity of several other enzymes in isolated synaptic mitochondria [135]. Impaired mitochondrial
function is often associated with increased oxidative damage.
This may in part explain the increase in reactive oxygen
species in the presence of ammonia. Increased ammonia
production would either necessitate urea cycle function
to metabolize the toxic ammonia to urea or necessitate
increased reaction of ammonia with glutamate catalyzed by
glutamine synthetase followed by export of glutamine from
the brain. Evidence from studies of the urea cycle and amino
acid metabolism in AD subjects and mouse models justifies
further investigation of the regulation of the production and
detoxification of ammonia in the AD brain.

7. Considerations for Dietary Metabolite
Supplementation as a Treatment for AD
Increasing or decreasing the levels of specific amino acids
and other metabolites in the diet has shown some promise
for improving markers of aging and longevity [41]; so it is
possible that nutrient supplementation or restriction may
improve neural functioning in AD patients because age is
the major risk factor for AD. However, there are several
hurdles to overcome before an efficacious treatment can
be formulated. For example, studies on intestinal transport,
bioavailability, hepatic metabolism and excretion, and bloodbrain barrier transport are needed in order to choose the
optimal formulations. Much of this information is present
for a few commonly studied amino acids, but much of it
is absent for the majority of the amino acids. From what
is known, it appears that hepatic metabolism presents a
large challenge to overcome for the supplementation of
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many of the amino acids for their use in the treatment of
neurodegeneration, but intestinal transport may also become
limiting in the elderly [106]. Several of the amino acids
also have limited blood-brain barrier permeability. We will
present one promising strategy below taking these many
challenges into consideration.
As mentioned previously, intestinal uptake of amino acids
declines past age 65. It has been shown that the bioavailability
of individual amino acids and dipeptides is slightly better
than that of amino acids consumed as polypeptides since the
individual monomers can be absorbed quickly without the
need for further enzymatic hydrolysis in the gut. Therefore,
dietary supplementation with individual amino acids or combinations of individual amino acids would likely benefit the
elderly in addition to a high protein diet that promotes health
in this age group [106]. The use of individual amino acids
also has the added benefit of being able to stimulate specific
signaling pathways. Due to the decreased intestinal uptake of
amino acids in the elderly, they may particularly benefit from
supplementation with hydrophobic, more membrane permeable forms of amino acids such as amino acid ethyl esters
or N-acetyl amino acids. These amino acid derivatives show
a greater probability of diffusion across membrane bilayers
such as intestinal epithelia and the capillary endothelia of the
blood-brain barrier where the activity of specific membrane
transporters may be limiting. These more hydrophobic amino
acid derivatives are cleaved by esterases and other hydrolytic
enzymes intracellularly or extracellularly to release the free
amino acid. This hydrolysis may occur to a large extent
during first pass hepatic metabolism, so this strategy may
be of marginal use for increasing the blood-brain barrier
permeability for many amino acids.
Dietary aspartate, glutamate, and glutamine are oxidized as primary sources of fuel for intestinal cells [136].
In addition, glutamate and aspartate are transported very
poorly through the blood-brain barrier [137], even though
they are present at high concentrations in the brain. Other
amino acids that are transported poorly through the bloodbrain barrier include glycine, alanine, proline, and GABA.
Medium and large side chain, nonpolar amino acids are
transported relatively well by the blood-brain barrier into the
brain, including aromatic amino acids, BCAAs, methionine,
histidine, and threonine [138]. Glutamine and asparagine are
also likely transported by the same pathway. These amino
acids all compete for transport through the L1 transport
pathway. Another amino acid transporter called the y+ system
transports basic amino acids such as arginine, lysine, and
ornithine as well as several neutral amino acids such as
serine through the blood-brain barrier [137]. One potential
therapeutic strategy for AD patients is to supplement low protein diets with high levels of BCAAs, aromatic amino acids,
glutamine, histidine, and threonine. Through competition
for the L1 amino acid transport system, this therapy could
limit the transport of methionine into the brain, perhaps
yielding the known metabolic and neuroprotective benefits
of methionine restriction [30, 44]. However, methionine is
also transported into the brain to a limited extent through
the y+ system, which may hinder the effectiveness of this
strategy. A second potential therapy is to omit leucine and/or
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Figure 2: Select alterations affecting amino acid metabolism in Alzheimer’s disease brain. (a) Several pathogenic processes occurring in
Alzheimer’s disease brain. The bold arrow indicates that tryptophan metabolism in the kynurenine pathway may be increased relative to the
serotonin pathway in AD, contributing to the lower tryptophan levels observed. (b) Select mechanisms through which the Alzheimer’s disease
brain attempts to maintain homeostasis when faced with decreased glucose catabolism and increased amino acid catabolism and ammonia
levels.

isoleucine instead of methionine from the previously mentioned supplementation strategy. These two amino acids are
not transported by the y+ system [137]. Depletion of leucine
or isoleucine in the brain could lead to amino acid imbalance,
activation of GCN2 kinase, and possibly the inhibition of
mTOR kinase to slow protein translation rates that may be
beneficial for reducing the levels of neurofibrillary tangles
formed from hyperphosphorylated aggregates of tau protein. These amino acid supplementation therapies could be
combined with supplementation with other metabolic fuels
such as D-beta-hydroxybutyrate (a ketone body), citric acid
cycle intermediates, pyruvate, and/or lactate, which would
decrease the reliance of AD neurons on the use of amino
acids as a fuel. Consumption of high levels of these alternative
metabolic fuels may be able to partially restore neuronal
amino acid levels.

altered amino acid metabolism that occurs in AD is shown in
Figure 2.
The measurement of metabolite levels provides a snapshot of a very dynamic process. While this information is
extremely useful, it is not sufficient by itself to understand
the pathological changes associated with AD. Further studies
measuring enzyme activities could provide complementary
information about the dynamics of amino acid metabolism
in AD. In addition, studies overexpressing OTC and ARG2
to activate the urea cycle in the brain endothelial cells of an
AD mouse model would help clarify the effects of endothelial urea cycle activity on brain physiology and cognitive
function. Studying AD from a metabolic perspective could
lead to dietary supplementation therapies that delay disease
progression or alleviate some of the suffering caused by the
disease.

8. Summary and Conclusion
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C. Ibáñez, C. Simó, P. J. Martı́n-Álvarez et al., “Toward a predictive model of Alzheimer’s disease progression using capillary
electrophoresis-mass spectrometry metabolomics,” Analytical
Chemistry, vol. 84, no. 20, pp. 8532–8540, 2012.
R. Kaddurah-Daouk, H. Zhu, S. Sharma et al., “Alterations
in metabolic pathways and networks in Alzheimer’s disease,”
Translational Psychiatry, vol. 3, article e244, 2013.
Y. Liu, N. Li, L. Zhou, Q. Li, and W. Li, “Plasma metabolic
profiling of mild cognitive impairment and Alzheimer’s disease
using liquid chromatography/mass spectrometry,” Central Nervous System Agents in Medicinal Chemistry, vol. 14, no. 2, pp.
113–120, 2014.
S. F. Graham, O. P. Chevallier, C. T. Elliott et al., “Untargeted
metabolomic analysis of human plasma indicates differentially
affected polyamine and L-Arginine metabolism in mild cognitive impairment subjects converting to alzheimer’s disease,”
PLoS ONE, vol. 10, no. 3, Article ID e0119452, 2015.

12
[37] K. Klavins, T. Koal, G. Dallmann, J. Marksteiner, G. Kemmler, and C. Humpel, “The ratio of phosphatidylcholines to
lysophosphatidylcholines in plasma differentiates healthy controls from patients with Alzheimer’s disease and mild cognitive
impairment,” Alzheimer’s & Dementia: Diagnosis, Assessment &
Disease Monitoring, vol. 1, no. 3, pp. 295–302, 2015.
[38] S. Mathew, S. Krug, T. Skurk et al., “Metabolomics of Ramadan
fasting: an opportunity for the controlled study of physiological
responses to food intake,” Journal of Translational Medicine, vol.
12, no. 1, article 161, 2014.
[39] E. Trushina, T. Dutta, X.-M. T. Persson, M. M. Mielke, and R.
C. Petersen, “Identification of altered metabolic pathways in
plasma and CSF in mild cognitive impairment and Alzheimer’s
disease using metabolomics,” PLOS ONE, vol. 8, no. 5, Article
ID e63644, 2013.
[40] J. Zheng, R. A. Dixon, and L. Li, “Development of isotope labeling LC-MS for human salivary metabolomics and application to
profiling metabolome changes associated with mild cognitive
impairment,” Analytical Chemistry, vol. 84, no. 24, pp. 10802–
10811, 2012.
[41] J. D. Fernstrom, “Branched-chain amino acids and brain function,” Journal of Nutrition, vol. 135, no. 6, supplement, pp. 1539S–
1546S, 2005.
[42] E. Parrella, T. Maxim, F. Maialetti et al., “Protein restriction
cycles reduce IGF-1 and phosphorylated tau, and improve
behavioral performance in an Alzheimer’s disease mouse
model,” Aging Cell, vol. 12, no. 2, pp. 257–268, 2013.
[43] L. Fontana, N. Cummings, S. A. Apelo et al., “Decreased consumption of branched-chain amino acids improves metabolic
health,” Cell Reports, vol. 16, no. 2, pp. 520–530, 2016.
[44] I. Sanchez-Roman and G. Barja, “Regulation of longevity and
oxidative stress by nutritional interventions: role of methionine
restriction,” Experimental Gerontology, vol. 48, no. 10, pp. 1030–
1042, 2013.
[45] M. V. Morabito, D. E. Berman, R. T. Schneider, Y. Zhang, R. L.
Leibel, and S. A. Small, “Hyperleucinemia causes hippocampal
retromer deficiency linking diabetes to Alzheimer’s disease,”
Neurobiology of Disease, vol. 65, pp. 188–192, 2014.
[46] G. Scaini, L. M. Mello-Santos, C. B. Furlanetto et al., “Acute
and chronic administration of the branched-chain amino acids
decreases nerve growth factor in rat hippocampus,” Molecular
Neurobiology, vol. 48, no. 3, pp. 581–589, 2013.
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